Third Party Disclosure. Notwithstanding anything in this Section 8, either Party may share the existence and terms of this Agreement and Enumeral Confidential Information related to the First Antibody with Third Parties under an obligation of confidentiality at least as restrictive as those of this Agreement and the CDA (as defined below) without the prior consent of the other Party. This includes the right to provide such information to potential investors in order to facilitate investment financing in connection with the development of one or more Products by Pieris. In all events, each Party remains subject to its obligations set forth herein and in the CDA.
Appears in 4 contracts
Samples: License and Transfer Agreement (Pieris Pharmaceuticals, Inc.), License and Transfer Agreement (Enumeral Biomedical Holdings, Inc.), License and Transfer Agreement (Enumeral Biomedical Holdings, Inc.)
Third Party Disclosure. Notwithstanding anything in this Section 8, either Party may share the existence and terms of this Agreement Agreement, the Original Agreement, and Enumeral Confidential Information related to the First Antibody and, if applicable, Subsequent Antibody with Third Parties under an obligation of confidentiality at least as restrictive as those of this Agreement and the CDA (as defined below) without the prior consent of the other Party. This includes the right to provide such information to potential investors in order to facilitate investment financing in connection with the development of one or more Products by Pieris. In all events, each Party remains subject to its obligations set forth herein and in the CDA.
Appears in 2 contracts
Samples: License and Transfer Agreement (Enumeral Biomedical Holdings, Inc.), Confidential Treatment Requested (Pieris Pharmaceuticals, Inc.)
